We are happy to announce that we have successfully concluded a Phase III Anal Fissure study.
A US-based biotech started a Phase III Anal Fissure indication study in the USA, Canada and Israel. Due to slow recruitment from the initial sites HungaroTrial was contacted to initate a rescue study.
HungaroTrial quickly moved from agreement to settign up sites in Poland, Ukraine, and Bulgaria and proceeded to enroll the required number of patients in two months. Due to the hard work of the HT team, the initiation and completion of the study – from the first phone call with the sponsor to locking the project database for nearly 100 patients – was completed in only 10 months.